Insulin and IGFs in renal cancer risk and progression

Endocrine-Related Cancer

Volumn 22, Issue 5, 2015, Pages R253-R264

  Solarek, W ^a,b   Czarnecka, A M ^a   Escudier, B ^c   Bielecka, Z F ^a,b   Lian, F ^d   Szczylik, C ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Insulin; Insulin receptor; Insulin like growth factor; Insulin like growth factor receptor; Obesity; Renal cell carcinoma

Indexed keywords

INSULIN; RECEPTOR FOR ACTIVATED C KINASE 1; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VON HIPPEL LINDAU PROTEIN;

CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CARCINOMA CELL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY CANCER; NONHUMAN; OBESITY; REVIEW; SIGNAL TRANSDUCTION; ADULT; COMPLICATION; KIDNEY NEOPLASMS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY NEOPLASMS; RISK FACTORS;

EID: 84942084155     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0135     Document Type: Review

References (87)

1. Adams DR, Ron D & Kiely PA 2011 RACK1, a multifaceted scaffolding protein: structure and function. Cell Communication and Signaling 9 22. (doi:10.1186/1478-811X-9-22)
2. Ahmad N, Keehn CA & Coppola D 2004 The expression of insulin-like growth factor-I receptor correlates with Fuhrman grading of renal cell carcinomas. Human Pathology 35 1132-1136. (doi:10.1016/j.humpath. 2004.05.012)
3. Antonelli A, Arrighi N, Corti S, Zanotelli T, Cozzoli A, Cosciani Cunico S & Simeone C 2013 Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study. Urologic Oncology 31 1310-1315. (doi:10.1016/j. urolonc.2011.12.013)
4. Belfiore A 2007 The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Current Pharmaceutical Design 13 671-686. (doi:10.2174/138161207780249173)
5. Berry MG & Helwig FC 1948 Marked insulin resistance in diabetes mellitus. American Journal of Medicine 4 923-926. (doi:10.1016/0002-9343(48)0490-2)
6. Brouwer-Visser J & Huang GS 2015 IGF2 signaling and regulation in cancer. Cytokine & Growth Factor Reviews 26 371-377. (doi:10.1016/j.cytogfr. 2015.01.002)
7. Cardillo TM, Trisal P, Arrojo R, Goldenberg DM & Chang C-H 2013 Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer 13 170. (doi:10.1186/1471-2407-13-170)
8. Chen HX & Sharon E 2013 IGF-1R as an anti-cancer target - trials and tribulations. Chinese Journal of Cancer 32 242-252. (doi:10.5732/cjc.012.10263)
9. Cheung CW, Vesey DA, Nicol DL & Johnson DW 2004 The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation. Kidney International 65 1272-1279. (doi:10.1111/j.1523-1755.2004.00535.x)
10. Cheung C, Vesey D, Cotterill A, Douglas M, Gobe G, Nicol D & Johnson D 2005 Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. International Journal of Urology 12 17-28. (doi:10.1111/j.1442-2042.2004.00993.x)
11. Chow W-H, Gridley G, Fraumeni JF Jr & Järvholm B 2000 Obesity, hypertension, and the risk of kidney cancer in men. New England Journal of Medicine 343 1305-1311. (doi:10.1056/NEJM200011023431804)
12. Chuang S-T, Patton KT, Schafernak KT, Papavero V, Lin F, Baxter RC, Teh BT & Yang XJ 2008 Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. Journal of Urology 179 445-449. (doi:10.1016/j.juro.2007.09.106)
13. Datta K 2000 Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. Journal of Biological Chemistry 275 20700-20706. (doi:10.1074/jbc. M909970199)
14. Dombrowski F, Klotz L, Bannasch P & EvertM2007 Renal carcinogenesis in models of diabetes in rats - metabolic changes are closely related to neoplastic development. Diabetologia 50 2580-2590. (doi:10.1007/s00125-007-0838-2)
15. Donat SM, Salzhauer EW, Mitra N, Yanke BV, Snyder ME & Russo P 2006 Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. Journal of Urology 175 46-52. (doi:10.1016/S0022-5347(05)0054-6)
16. Dong LM, Brennan P, Karami S, Hung RJ, Menashe I, Berndt SI, Yeager M, Chanock S, Zaridze D, Matveev V et al. 2009 An analysis of growth, differentiation and apoptosis genes with risk of renal cancer. PLoS ONE 4 e4895. (doi:10.1371/journal.pone.0004895)
17. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278-3288.
18. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A & Vigneri R 2008 The role of insulin receptors and IGF-I receptors in cancer and other diseases. Archives of Physiology and Biochemistry 114 23-37. (doi:10.1080/13813450801969715)
19. Fukushima H, Masuda H, Yokoyama M, Tatokoro M, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Koga F, Saito K et al. 2013 Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology 43 740-746. (doi:10.1093/jjco/hyt070)
20. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al. 2012 Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 366 883-892. (doi:10.1056/NEJMoa1113205)
21. Goodman MT, Morgenstern H & Wynder EL 1986 A case-control study of factors affecting the development of renal cell cancer. American Journal of Epidemiology 124 926-941.
22. Gupta K, Miller JD, Li JZ, Russell MW & Charbonneau C 2008 Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treatment Reviews 34 193-205. (doi:10.1016/j.ctrv.2007.12.001)
23. Ha Y-S, Kim WT, Yun S-J, Lee S-C, Kim W-J, Park YH, Kang SH, Hong S-H, Byun S-S & Kim Y-J 2013 Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Annals of Surgical Oncology 20 3662-3668. (doi:10.1245/s10434-013-3147-7)
24. Habib SL & Liang S 2014 Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes. Oncotarget 5 2542-2550.
25. He X, Wang J, Messing EM & Wu G 2010 Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene 30 535-547. (doi:10.1038/onc.2010.427)
26. Hintz RL, Bock S, Thorsson AV, Bovens J, Powell DR, Jakse G & Petrides PE 1991 Expression of the insulin like growth factor-binding protein 3 (IGFBP-3) gene is increased in human renal carcinomas. Journal of Urology 146 1160-1163.
27. Hirschberg R & Adler S 1998 Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications. American Journal of Kidney Diseases 31 901-919. (doi:10.1053/ajkd.1998.v31.pm9631833)
28. Hjartaker A, Langseth H & Weiderpass E 2008 Obesity and diabetes epidemics: cancer repercussions. Advances in Experimental Medicine and Biology 630 72-93.
29. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG & Cairns P 2006 Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Research 66 5021-5028. (doi:10.1158/0008-5472.CAN-05-3365)
30. Joh H-K, Willett WC & Cho E 2011 Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 34 1552-1556. (doi:10.2337/dc11-0132)
31. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P & Halmos G 1997 Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. PNAS 94 5810-5813. (doi:10.1073/pnas.94.11.5810)
32. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J & Armatis P 1998 Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer 82 909-917. (doi:10.1002/(SICI)097-0142(19980301)82:5!909::AID-CNCR16O3.0.CO;2-4)
33. Kaneda A, Wang CJ, Cheong R, Timp W, Onyango P, Wen B, Iacobuzio-Donahue CA, Ohlsson R, Andraos R, Pearson MA et al. 2007 Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. PNAS 104 20926-20931. (doi:10.1073/pnas.0710359105)
34. Kara I, Poggi M, Bonardo B, Govers R, Landrier J-F, Tian S, Leibiger I, Day R, Creemers JW & Peiretti F 2015 The paired basic amino acid-cleaving enzyme 4 (PACE4) is involved in the maturation of insulin receptor isoform B: an opportunity to reduce the specific insulin receptor-dependent effects of insulin-like growth factor 2 (IGF2). Journal of Biological Chemistry 290 2812-2821. (doi:10.1074/jbc.M114. 592543)
35. Kellerer M, von Eye Corleta H, Mühlhöfer A, Capp E, Mosthaf L, Bock S, Petrides PE & Häring HU 1995 Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. International Journal of Cancer. Journal International du Cancer 62 501-507. (doi:10.1002/ijc.2910620502)
36. Kosti A, Chen H-IH, Mohan S, Liang S, Chen Y & Habib SL 2015 Microarray profile of human kidney from diabetes, renal cell carcinoma and renal cell carcinoma with diabetes. Genes & Cancer 6 62.
37. Larsson SC & Wolk A 2011 Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54 1013-1018. (doi:10.1007/s00125-011-2051-6)
38. Lauder I, Abascal J, Cartwright RA, Farndon JR & Johnston ID 1981 Liver tumours following streptozotocin administration in rats and the effects of pancreatic islet cell transplantation. Carcinogenesis 2 799-803. (doi:10.1093/carcin/2.8.799)
39. Leboulleux S, Gaston V, Boulle N, Le Bouc Y & Gicquel C 2001 Loss of heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor locus: a frequent but late event in adrenocortical tumorigenesis. European Journal of Endocrinology/European Federation of Endocrine Societies 144 163-168. (doi:10.1530/eje.0.1440163)
40. Lee S, Hong SK, Kwak C, Kim HH & Lee SE 2012 Prognostic significance of diabetes mellitus in localized renal cell carcinoma. Japanese Journal of Clinical Oncology 42 318-324. (doi:10.1093/jjco/hys018)
41. Lindblad P, Chow WH, Chan J, Bergström A, Wolk A, Gridley G, McLaughlin JK, Nyren O & Adami HO 1999 The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42 107-112. (doi:10.1007/s001250051122)
42. Lissoni P, Barni S, Ardizzoia A, Frigerio F, Paolorossi F, Cazzaniga M, Tancini G, Rocco F & Aapro M 1995 Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1. Tumori 81 261-264.
43. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S & Kiemeney LA 2011 The epidemiology of renal cell carcinoma. European Urology 60 615-621. (doi:10.1016/j.eururo.2011.06.049)
44. Lkhagvadorj S, Oh SS, Lee MR, Jung JH, Chung HC, Cha SK & Eom M 2014 Insulin receptor expression in clear cell renal cell carcinoma and its relation to prognosis. Yonsei Medical Journal 55 861-870. (doi:10.3349/ymj.2014.55.4.861)
45. Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM & Russo P 2010 Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU International 105 16-20. (doi:10.1111/j.1464-410X.2009.08706.x)
46. Maeng Y-S, Choi H-J, Kwon J-Y, Park Y-W, Choi K-S, Min J-K, Kim Y-H, Suh P-G, Kang K-S, Won M-H et al. 2009 Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCb2 axis. Blood 113 233-243. (doi:10.1182/blood-2008-06-162891)
47. Major JM, Pollak MN, Snyder K, Virtamo J & Albanes D 2010 Insulin-like growth factors and risk of kidney cancer in men. British Journal of Cancer 103 132-135. (doi:10.1038/sj.bjc.6605722)
48. Mastick CC, Kato H, Roberts CT Jr, LeRoith D & Saltiel AR 1994 Insulin and insulin-like growth factor-I receptors similarly stimulate deoxyribonucleic acid synthesis despite differences in cellular protein tyrosine phosphorylation. Endocrinology 135 214-222.
49. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A & McClain DA 1990 Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO Journal 9 2409-2413.
50. Murai M & Oya M 2004 Renal cell carcinoma: etiology, incidence and epidemiology. Current Opinion in Urology 14 229-233. (doi:10.1097/01.mou.0000135078.04721.f5)
51. Nonomura N, Nishimura K, Miki T, Kanno N, Kojima Y, Yokoyama M & Okuyama A 1997 Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma. Cancer Research 57 2575-2577.
52. O'Mara BA, Byers T & Schoenfeld E 1985 Diabetes mellitus and cancer risk: a multisite case-control study. Journal of Chronic Diseases 38 435-441. (doi:10.1016/0021-9681(85)0139-0)
53. Oda H, Kume H, Shimizu Y, Inoue T & Ishikawa T 1998 Loss of imprinting of IGF2 in renal-cell carcinomas. International Journal of Cancer. Journal International du Cancer 75 343-346. (doi:10.1002/(SICI)097-0215(19980130)75:3!343::AID-IJC3O3.0.CO;2-2)
54. Parker AS, Cheville JC, Janney CA & Cerhan JR 2002 High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Human Pathology 33 801-805. (doi:10.1053/hupa.2002.126186)
55. Parker A, Cheville JC, Lohse C, Cerhan JR & Blute ML 2003 Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. Journal of Urology 170 420-424. (doi:10.1097/01.ju.0000071474.70103.92)
56. Parker AS, Cheville JC, Blute ML, Igel T, Lohse CM & Cerhan JR 2004 Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer 100 2577-2582. (doi:10.1002/cncr.20322)
57. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 8 915-928. (doi:10.1038/nrc2536)
58. Rabkin R & Schaefer F 2004 New concepts: growth hormone, insulin-like growth factor-I and the kidney. Growth Hormone & IGF Research 14 270-276. (doi:10.1016/j.ghir.2004.02.001)
59. Rasmuson T, Grankvist K, Jacobsen J, Olsson T & Ljungberg B 2004 Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncologica 43 744-748. (doi:10.1080/02841860410017260)
60. Renehan AG, Tyson M, Egger M, Heller RF & Zwahlen M 2008 Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 569-578. (doi:10.1016/S0140-6736(08)0269-X)
61. Rosendahl A & Forsberg G 2004 Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. International Journal of Oncology 25 1327.
62. Rosendahl AH & Forsberg G 2006 IGF-I and IGFBP-3 augment transforming growth factor-b actions in human renal carcinoma cells. Kidney International 70 1584-1590. (doi:10.1038/sj.ki.5001805)
63. Rosendahl AH, Holly JM, Celander M & Forsberg G 2008 Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. International Journal of Cancer. Journal International du Cancer 123 1286-1291. (doi:10.1002/ijc.23642)
64. SafarinejadMR 2011 Insulin-like growth factor binding protein-3 (IGFBP-3) gene variants are associated with renal cell carcinoma. BJU International 108 762-770. (doi:10.1111/j.1464-410X.2010.09809.x)
65. Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM& KobayashiM1996 Comparison of the insulin and insulinlike growth factor 1 mitogenic intracellular signaling pathways. Endocrinology 137 4427-4434.
66. Schips L, Zigeuner R, Ratschek M, Rehak P, Rüschoff J & Langner C 2004 Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. American Journal of Clinical Pathology 122 931-937. (doi:10.1309/G7PY0RE 7T86HHQYV)
67. Segev Y, Landau D, Marbach M, Shehadeh N, Flyvbjerg A & Phillip M 1997 Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I. Journal of the American Society of Nephrology 8 436-444.
68. Sen S, Talukdar I & Webster NJ 2009 SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Molecular and Cellular Biology 29 871-880. (doi:10.1128/MCB.01709-08)
69. Sichani MM, Yazdi FS, Moghaddam NA, Chehrei A, Kabiri M, Naeimi A & Taheri D 2010 Prognostic value of insulin-like growth factor-I receptor expression in renal cell carcinoma. Saudi Journal of Kidney Diseases and Transplantation 21 69-74.
70. Siddle K 2012 Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances. Frontiers in Endocrinology 3 34. (doi:10.3389/fendo.2012.00034)
71. Soos MA, Whittaker J, Lammers R, Ullrich A & Siddle K 1990 Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochemical Journal 270 383-390.
72. Spyridopoulos TN, Dessypris N, Antoniadis AG, Gialamas S, Antonopoulos CN, Katsifoti K, Adami H-O, Chrousos GP, Petridou ET & Obesity and Cancer Oncology Group 2012 Insulin resistance and risk of renal cell cancer: a case-control study. Hormones 11 308-315. (doi:10.14310/horm.2002.1359)
73. Süer E, Öztürk E, Gülpinar Ö, Kayiş A & Baltaci S 2013 Effect of type 2 diabetes mellitus on prognosis of nonmetastatic renal cell cancer. Korean Journal of Urology 54 499.
74. Takahashi M, Papavero V, Yuhas J, Kort E, Kanayama H-O, Kagawa S, Baxter RC, Yang XJ, Gray SG & Teh BT 2005 Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. International Journal of Oncology 26 923-931.
75. Vavallo A, Simone S, Lucarelli G, Rutigliano M, Galleggiante V, Grandaliano G, Gesualdo L, Campagna M, Cariello M, Ranieri E et al. 2014 Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine 93 e183. (doi:10.1097/MD.0000000000000183)
76. Vinerean HV,Gazda LS,Hall RD & Smith BH 2011 Streptozotocin is responsible for the induction andprogressionof renal tumorigenesis indiabeticWistar-Furth rats treated with insulin or transplanted with agarose encapsulated porcine islets. Islets 3 196-203. (doi:10.4161/isl.3.4.16129)
77. Wan X, Harkavy B, Shen N, Grohar P& Helman LJ 2006 Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26 1932-1940. (doi:10.1038/sj.onc.1209990)
78. Wang G, Hou J, Ma L, Xie J, Yin J, Xu D, Chang W, Tan X, Su T, Zhang H et al. 2012 Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study. Cancer Epidemiology 36 177-182. (doi:10.1016/j.canep.2011.09.006)
79. Washio M, Mori M, Khan M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, Miki T, Nakao M, Mikami K et al. 2007 Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study): diabetes mellitus and kidney cancer. International Journal of Urology 14 393-397. (doi:10.1111/j.1442-2042.2007.01744.x)
80. Wei M, Ong L, Smith MT, Ross FB, Schmid K, Hoey AJ, Burstow D & Brown L 2003 The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart, Lung & Circulation 12 44-50. (doi:10.1046/j.1444-2892.2003.00160.x)
81. Werner H 2011 Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene 31 2703-2714. (doi:10.1038/onc.2011.447)
82. Werner H, Shen-Orr Z, Stannard B, Burguera B, Roberts CT & LeRoith D 1990 Experimental diabetes increases insulinlike growth factor I and II receptor concentration and gene expression in kidney. Diabetes 39 1490-1497. (doi:10.2337/diab.39.12.1490)
83. Werner H, Karnieli E, Rauscher FJ & LeRoith D 1996 Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. PNAS 93 8318-8323. (doi:10.1073/pnas.93. 16.8318)
84. Werner H, Weinstein D & Bentov I 2008 Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Archives of Physiology and Biochemistry 114 17-22. (doi:10.1080/13813450801900694)
85. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K & Olsen JH 1997 Cancer incidence in a populationbased cohort of patients hospitalized with diabetes mellitus in Denmark. Journal of the National Cancer Institute 89 1360-1365. (doi:10.1093/jnci/89.18.1360)
86. Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, Roberts IS, Pugh CW, Werner H & Macaulay VM 2007 The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26 6499-6508. (doi:10.1038/sj.onc.1210474)
87. Zhang T, Niu X, Liao L, Cho E-A & Yang H 2013 The contributions of HIF-target genes to tumor growth in RCC. PLoS ONE 8 e80544. (doi:10.1371/journal.pone.0080544)